COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (CMPS) granted equity awards to nine newly hired non-executive employees on November 2, 2026, under its 2026 Inducement Plan.
The awards comprise options to purchase 59,275 shares at an exercise price of $8.41 per share, plus restricted share units or, for UK employees, nominal cost options covering 28,200 shares. The exercise price equals the closing price of its American Depositary Shares on the grant date. The board’s Compensation and Leadership Development Committee approved the awards as employment inducements under Nasdaq Listing Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) management will participate in the Stifel 2026 Healthcare Conference on November 11, 2026.
The fireside chat is scheduled for 8:40am ET and will be available through a live audio webcast. A replay will remain accessible for 30 days following the event on the Events page in the Investors section of the Compass website.
Compass Pathways (Nasdaq: CMPS) reported a third-quarter net loss of $9.8 million as it advanced COMP360 toward regulatory submission.
The final New Drug Application for treatment-resistant depression is expected within two weeks. Compass targets a first-half 2027 launch, subject to FDA approval. Two positive Phase 3 trials support the application; 52-week open-label COMP005 data showed added benefit from an additional 25 mg dose, extending durability to one year.
Quarterly net loss narrowed from $137.7 million a year earlier, primarily reflecting non-cash warrant valuation changes. Research spending fell to $23.5 million from $27.3 million, while selling and administrative spending rose to $33.0 million from $13.2 million. Cash reached $444.0 million at September 30, versus $149.6 million at year-end; Compass expects funding into 2028. Debt rose to $51.0 million from $31.6 million. A late-stage post-traumatic stress disorder trial remains underway.
Compass Pathways (CMPS) and the Depression and Bipolar Support Alliance released a national survey report on treatment-resistant depression and caregiver experiences. The survey included 261 patients and 73 caregivers and measured self-reported experiences, not treatment outcomes. Treatment-resistant depression means an inadequate response to two or more adequately dosed antidepressant courses of sufficient duration.
95% of surveyed patients described themselves as functioning but struggling, surviving day-to-day or barely getting by. Almost 75% felt they had tried all available treatment options and were emotionally exhausted by unsuccessful treatments. Over 60% wished they had tried different approaches sooner after a treatment was not working. Approximately 70% of caregivers reported effects on the whole family's social, physical and/or mental health.
Compass Pathways (CMPS) will present research and treatment-resistant depression education at the NEI Fall Congress on November 5–8, 2026. The meeting takes place in Colorado Springs, Colorado.
The company will feature its Change the Tune in TRD campaign for U.S. healthcare professionals, with a panel discussion on November 8. Encore posters cover efficacy and safety findings from two Phase 3 controlled studies of investigational COMP360 psilocybin, plus participant demographic and clinical characteristics across two pivotal Phase 3 trials. No numerical clinical results are included in this announcement.
Compass Pathways (Nasdaq: CMPS) will release its third-quarter 2026 financial results and an update on recent developments on November 3, 2026. The results cover the quarter ended September 30, 2026. Management will host a conference call at 8:00 am ET (1:00 pm UK) that day. A live webcast will be available and archived for 30 days.
Compass Pathways (CMPS) announced the first U.S. Treatment-Resistant Depression Awareness Day to recognize people and caregivers affected by the condition. The campaign is being amplified by the National Alliance on Mental Illness, Mental Health America and the Depression and Bipolar Support Alliance. Treatment-resistant depression, or TRD, is broadly defined as an inadequate response to two or more appropriate courses of approved medications.
Compass said the awareness day aims to increase understanding, help people recognize signs earlier and encourage conversations about support. A new survey found that nearly 95% of respondents living with TRD described themselves as functioning but struggling, surviving day-to-day or barely getting by. Nearly two in three caregivers said TRD affects the whole family's social, physical and/or mental health. The full survey report will be shared in a future communication.
Compass Pathways (CMPS) granted equity awards to one senior leader and ten newly hired non-executive employees as employment inducements.
The senior leader’s September 30, 2026 awards comprised options for 121,800 shares at an exercise price of $12.44 and restricted share units covering 58,000 shares. The October 1, 2026 employee awards comprised options for 97,100 shares at $11.95 and restricted share units, or nominal cost options for UK employees, covering 46,200 shares.
The awards vest over four years, subject to continued employment. The board’s Compensation and Leadership Development Committee approved the grants under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) appointed Kelley Boucher as Chief People Officer, effective September 30, 2026, to oversee its people strategy.
Her initial focus will be guiding the company’s planned evolution toward launching COMP360 psilocybin. Compass plans a launch in the first half of 2027, subject to FDA approval, and is preparing to submit its new drug application in the fourth quarter of 2026. Boucher previously served as Chief People Officer at Apellis Pharmaceuticals and held human resources leadership roles at Alnylam Pharmaceuticals, Abiomed and Shire.
Compass Pathways (CMPS) will participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026, including a fireside chat at 1:00pm ET.
A live audio webcast of the fireside chat will be available via an online link, with a replay accessible for 30 days on the Investors “Events” page of the Compass website. Compass is developing its proprietary investigational COMP360 psilocybin for treatment-resistant depression and post-traumatic stress disorder and holds Breakthrough Therapy designation from the US FDA and ILAP designation in the UK for TRD.